SALVAGE CHEMOTHERAPY WITH BEVACIZUMAB-IRINOTECAN ASSOCIATION IN RECURRENT/REFRACTORY BRAIN TUMORS IN CHILDREN

被引：0
|
作者：
Schiavetti, A. [1 ]
Varrasso, G. [1 ]
Reale, G. [1 ]
De Grazia, A. [1 ]
Ferrara, E. [1 ]
Paiano, M. [1 ]
Clerico, A. [1 ]
机构：
[1] Univ Roma La Sapienza, I-00185 Rome, Italy
来源：
PEDIATRIC BLOOD & CANCER | 2014年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP-145
引用
收藏
页码：S286 / S286
页数：1
相关论文
共 50 条
  • [41] Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report
    Castelli, Barbara
    Fonte, Carla
    Guidi, Milena
    Tellini, Marco
    Di Nicola, Marco
    Iacono, Alessandro
    Buccoliero, Anna Maria
    Greto, Daniela
    Genitori, Lorenzo
    Sardi, Iacopo
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [42] A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors
    Vassal, G
    Doz, F
    Frappaz, D
    Imadalou, K
    Sicard, E
    Santos, A
    O'Quigley, J
    Germa, C
    Risse, ML
    Mignard, D
    Pein, F
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) : 3844 - 3852
  • [43] Irinotecan and bevacizumab in progressive primary brain tumors: The Cleveland Clinic experience
    Kang, T.
    Jin, T.
    Peereboom, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Phase I study of talazoparib and irinotecan in children and young adults with recurrent/refractory solid tumors.
    Federico, Sara Michele
    Stewart, Elizabeth
    Coleman, Jamie L.
    Bishop, Michael William
    Santana, Victor M.
    Lam, Catherine
    Hawkins, Dana
    Wu, Jianrong
    Mao, Shenghua
    Goshorn, David Ross
    Papp, Alberto S.
    Dyer, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety
    Tyler Y. Kang
    Tony Jin
    Heinrich Elinzano
    David Peereboom
    Journal of Neuro-Oncology, 2008, 89
  • [46] Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors
    Wagner, Lars
    Turpin, Brian
    Nagarajan, Rajaram
    Weiss, Brian
    Cripe, Timothy
    Geller, James
    PEDIATRIC BLOOD & CANCER, 2013, 60 (09) : 1447 - 1451
  • [47] Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety
    Kang, Tyler Y.
    Jin, Tony
    Elinzano, Heinrich
    Peereboom, David
    JOURNAL OF NEURO-ONCOLOGY, 2008, 89 (01) : 113 - 118
  • [48] EFFICACY OF BEVACIZUMAB PLUS IRINOTECAN IN CHILDREN WITH RECURRENT OR PROGRESSIVE MALIGNANT GLIOMA
    Arakawa, Yoshiki
    Umeda, Katsutsugu
    Watanabe, Ken-ichiro
    Mizowaki, Takashi
    Hiraoka, Masahiro
    Hiramatsu, Hidefumi
    Adachi, Souichi
    Kunieda, Takeharu
    Takagi, Yasushi
    Miyamoto, Susumu
    NEURO-ONCOLOGY, 2014, 16 : 59 - 59
  • [49] Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors
    Fiorillo, A
    Maggi, G
    Greco, N
    Migliorati, R
    D'Amico, A
    De Caro, MD
    Sabbatino, MS
    Buffardi, F
    JOURNAL OF NEURO-ONCOLOGY, 2004, 66 (1-2) : 179 - 185
  • [50] Second-line Chemotherapy with the Association of Liposomal Daunorubicin, Carboplatin and Etoposide in Children with Recurrent Malignant Brain Tumors
    Amedeo Fiorillo
    Giuseppe Maggi
    Nicola Greco
    Roberta Migliorati
    Alessandra D'Amico
    Marialaura Del Basso De Caro
    M. Simona Sabbatino
    Floriana Buffardi
    Journal of Neuro-Oncology, 2004, 66 : 179 - 185
12345